United States - English - NLM (National Library of Medicine)

rebel distributors corp - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 60 mg - fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with narrow-angle glaucoma or urinary retentio

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with narrow-angle glaucoma or urin

United States - English - NLM (National Library of Medicine)

chain drug consortium, llc - pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - pseudoephedrine hydrochloride 120 mg - nasal decongestant - temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies - temporarily relieves sinus congestion and pressure

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - pseudoephedrine hydrochloride 120mg - modified release capsule - 120 mg - active: pseudoephedrine hydrochloride 120mg

Canada - English - Health Canada

kv pharmaceutical company - pseudoephedrine hydrochloride - tablet (extended-release) - 120mg - pseudoephedrine hydrochloride 120mg - sympathomimetic (adrenergic) agents

Malta - English - Medicines Authority

ucb pharma sa 60 allee de la recherche, b-1070 brussels, belgium - cetirizine dihydrochloride, pseudoephedrine hydrochloride - prolonged-release tablet - cetirizine dihydrochloride 5 mg pseudoephedrine hydrochloride 120 mg - nasal preparations

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 60 mg - allegra-d 12 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 12 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 12 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 12 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe coronary arter

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 60 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate - fast temporary relief from a runny nose and reduce the swollen membranes of the nose and sinuses and helping breathe freely.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe co

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe coronary arter